COMPANY

Nob Hill Therapeutics

Profile checked Oct 10, 2026

Keywords: fungal infections NSCLC (Advanced Non-small Cell Lung Cancer) metastatic lung cancer NHT102

Timeline

Jan 11, 2027 Trial start Phase 1/Phase 2: Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer source ↗
Dec 20, 2024 Grant Government grant — SBIR: $1.14M (annual award, as published), announced Dec 20, 2024. Agency: NIH/NCI. Source: government award database. source ↗

Jul 13, 2029 (ESTIMATED) · Phase 1/Phase 2 · Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer · NCT07864584

Estimated primary completion per ClinicalTrials.gov. Dates move.

Last 2 years.

Dec 20, 2024 Government grant — SBIR: $1.14M (annual award, as published), announced Dec 20, 2024. Agency: NIH/NCI. Source: government award database. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07864584	Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer	Phase 1/Phase 2	Not yet recruiting	Jan 11, 2027	Jul 13, 2029 (estimated)

Annual award amounts. Total $2.9M.

Sep 19, 2023 NIH award 1R44CA281538-01A1 FY2023: $861,087 awarded for that fiscal year; activity R44 (SBIR); PI REED, MATTHEW; recipient as written: NOB HILL THERAPEUTICS, INC., Albuquerque, NM. Aerosolized Epigenetic Therapy for source ↗
Jun 19, 2023 NIH award 5R44HL147749-03 FY2023: $564,303 awarded for that fiscal year; activity R44 (SBIR); PI REED, MATTHEW; recipient as written: NOB HILL THERAPEUTICS, INC., Albuquerque, NM. Development of NH101: A Simple and E source ↗
Jun 28, 2022 NIH award 2R44HL147749-02 FY2022: $1,158,273 awarded for that fiscal year; activity R44 (SBIR); PI REED, MATTHEW; recipient as written: NOB HILL THERAPEUTICS, INC., Albuquerque, NM. Development of NH101: A Simple and source ↗
Feb 6, 2020 NIH award 1R43HL147749-01A1 FY2020: $299,058 awarded for that fiscal year; activity R43 (SBIR); PI REED, MATTHEW; recipient as written: NOB HILL THERAPEUTICS, INC., Albuquerque, NM. Development of NH101: A Simple and source ↗